Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | CLK3 | P49761 | 2/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174182 | 0.88 | CHRNB2 (0.48) | CHRNB2CHRNA4TLR7HRH3CYP11B1 | |
| SCHEMBL13744015 | 0.86 | HRH3 (0.59) | CYP2A6CHRNB2CHRNA4TLR7HRH3 | |
| SCHEMBL13778325 | 0.85 | HTR7 (0.46) | CYP2A6CHRNB2CHRNA4TLR7PRMT6 | |
| SCHEMBL3666911 | 0.80 | CYP2A6 (0.42) | CYP2A6CHRNB2CHRNA4DYRK1APRMT6 | |
| SCHEMBL13778403 | 0.77 | CYP11B1 (0.52) | CYP2A6CHRNB2CHRNA4TLR7HRH3 | |
| SCHEMBL13778380 | 0.77 | CYP2A6 (0.56) | CYP2A6DYRK1ACYP11B1CYP11B2CYP3A4 | |
| SCHEMBL3423606 | 0.77 | CYP2A6 (0.61) | CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL4165384 | 0.76 | CHRNB2 (0.39) | CHRNB2CHRNA4DYRK1APRMT6CLK2 | |
| SCHEMBL3426054 | 0.75 | CYP2A6 (0.59) | CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL3421746 | 0.75 | CYP2A6 (0.59) | CYP2A6CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CYP2A6 1045/4885CHRNB2 3774/4885CHRNA4 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.